MeOPP
From Wikipedia, the free encyclopedia
 |
MeOPP is part of WikiProject Pharmacology, a project to improve all Pharmacology-related articles. If you would like to help improve this and other pharmacology articles, please join the project. All interested editors are welcome. |
| Stub | This article has been rated as Stub-Class on the quality scale. |
|
|
|
 |
|
 |
|
|
MeOPP
|
|
| Systematic (IUPAC) name | |
| 1-(4-methoxyphenyl)piperazine | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C11H16N2O |
| Mol. mass | 192.258 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | hepatic |
| Half life | ? |
| Excretion | renal |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | oral |
4-methoxyphenylpiperazine (Paraperazine, MeOPP, 4-MeOPP) is a piperazine derivative with stimulant effects which has been sold as an ingredient in "Party pills", initially in New Zealand and subsequently in other countries around the world.
MeOPP has been found in vitro to inhibit monoamine re-uptake and stimulate their release. This is a mechanism of action shared with drugs of abuse such as amphetamines, and MeOPP produces somewhat similar effects although it is much less potent and is thought to have relatively insignificant abuse potential. [1] Piperazine derivatives such as TFMPP have also been shown to exert a major part of their mechanism of action as non-selective serotonin agonists, and MeOPP has also been demonstrated to act in this way. [2] MeOPP is anecdotally said to induce significantly less anxiety than similar piperazines, and is usually taken at doses between 120 - 200mg. It does not produce prominent stimulant effects, but is instead said to be relaxing[citation needed], however it is often mixed with stimulant piperazine derivatives such as BZP for a combined effect.
Based on the recommendation of the EACD, the New Zealand government has passed legislation which placed BZP, along with the other piperazine derivatives TFMPP, mCPP, pFPP, MeOPP and MBZP, into Class C of the New Zealand Misuse of Drugs Act 1975. A ban was intended to come into effect in New Zealand on December 18th 2007, but the law change did not go through until the following year, and the sale of BZP and the other listed piperazines became illegal in New Zealand as of 1st of April 2008. An amnesty for possession and usage of these drugs will remain until October 2008, at which point they will become completely illegal.[3]
[edit] See also
[edit] External links
[edit] References
- ^ Nagai F, Nonaka R, Satoh Hisashi Kamimura K. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. European Journal of Pharmacology. 2006 Dec 12; [Epub ahead of print]
- ^ Maurer HH, Kraemer T, Springer D, Staack RF. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Therapeutic Drug Monitoring. 2004 Apr; 26(2): 127-31.
- ^ Misuse of Drugs (Classification of BZP) Amendment Bill 2008
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
